Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05430373
Other study ID # GT101-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 23, 2022
Est. completion date December 31, 2025

Study information

Verified date October 2023
Source Grit Biotechnology
Contact Haifeng Qin, PhD
Phone +86 13601365243
Email hifo@263.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, clear lung pretreatment period, treatment and observation period, and follow-up period. The study is designed to enroll 20-31 subjects, with 14-20 subjects expected to be evaluable, in an "autologous tumor-infiltrating lymphocyte therapy" regimen that includes: 1. Clear lymphatic pretreatment (FC regimen: cyclophosphamide + fludarabine). 2. GT101 infusion. 3. post-infusion treatment (interleukin-2 intravenous push).


Recruitment information / eligibility

Status Recruiting
Enrollment 31
Est. completion date December 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - 1. The Patients (or legally authorized representative) Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), must have the ability to understand the requirements of the study; - 2.Must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies: unresectable recurrent or metastatic solid tumor; - 3.At least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies. The separated tissues mass weighing =1.0g (either of single lesion origin or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes. Minimally invasive treatment where possible; - 4.Any anti-tumor therapy should be stopped at least 28 days before NMA lymphodepletion pretreatment; Exclusion Criteria: - 1. Patients who have symptomatic and/or untreated CNS metastases (Except stable brain metastases, no medication required within 3 months, no hormone dependence); - 2.The patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (>10 mg/day of prednisone or equivalent hormone); - 3. Arterial/venous thrombotic events within 5 months prior to enrollment, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring; - 4.Active infections requiring treatment with systemic anti-infectives (except for topical antibiotics); or those with unexplained fever > 38.5? occurring during the screening period, except for tumor fever; - 5. Patients who have refractory or intractable epilepsy, poorly controlled hydrothorax, hydrops abdominis, active gastrointestinal bleeding or IL-2 contraindications; - 6. Participate in other clinical trials within 28 days prior to the first dose of this study, or planning to participate in this study and other clinical trials at the same - 7. Patients who have received allogeneic bone marrow transplantation or an organ allograft; - 8.Patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin);

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
GT101
Autologous tumor infiltrating lymphocyte injection

Locations

Country Name City State
China The fifth medical center of the General Hospital of the Chinese people's Liberation Army Beijing Beijing
China West China School of Medicine/West China Hospital of Sichuan University Chengdu Sichuan
China Chongqing University Cancer Center Chongqing Chongqing
China Fudan University Shanghai Cancer Center Shanghai Shanghai
China Tianjin Medical University Cancer Institute & Hospital Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Grit Biotechnology

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Profile Measured by Grade =3 TEAEs To characterize the safety profile of autologous TIL injection(GT101) in patients with relapsed/metastatic advanced solid tumor as measured by the incidence of Grade = 3 treatment-emergent adverse events (TEAEs) 3 years
Primary Objective response rate To evaluate efficacy parameters such Objective Response Rate (ORR) per RECIST 1.1, as assessed by the Investigator 3 years
Primary Progression-free survival To evaluate efficacy parameters such Progression-Free Survival (PFS) per RECIST 1.1, as assessed by the Investigator 3 years
Primary Overall survival To evaluate efficacy parameters such Overall Survival (OS) 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT06404528 - Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours N/A
Terminated NCT04467853 - A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors Phase 1
Terminated NCT05698888 - Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors Phase 1
Recruiting NCT04587479 - A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors Phase 1
Withdrawn NCT05472220 - Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma Phase 1
Recruiting NCT05354323 - NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors Phase 1
Recruiting NCT04739293 - Study of ON 123300 in Patients With Advanced Cancer Phase 1
Not yet recruiting NCT05747339 - A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors N/A
Recruiting NCT05887492 - Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05228015 - Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05018273 - Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors Phase 1
Recruiting NCT04621435 - Imaging of Solid Tumors Using FAP-2286 Phase 1
Recruiting NCT05861895 - A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors Phase 1
Recruiting NCT06088472 - TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors Early Phase 1
Recruiting NCT05768139 - First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Phase 1/Phase 2